Advertisement

Hawthorn

  • Timothy S. Tracy
Chapter
Part of the Forensic Science and Medicine book series (FSM)

Abstract

Hawthorn appears to be effective for the treatment of stage II congestive heart failure. The mechanism(s) by which hawthorn exerts this positive effect is still unclear as results regarding changes in particular cardiovascular parameters are mixed. Human clinical studies of the use of hawthorn in other cardiovascular conditions are lacking. Adverse effects of hawthorn therapy appear to be mild and no significant drug interactions have been reported (though, in theory it might potentiate the effect of vasodilators).

Key Words

Crataegus oxyacantha heart failure hypertension vasodilation digoxin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous. Lawrence Review of Natural Products. St. Louis: Facts and Comparisons, 1994.Google Scholar
  2. 2.
    Hamon NW. Herbal medicine: Hawthorns (Genus crataegus). Can Pharmaceut J 1988;121:708–709,724.Google Scholar
  3. 3.
    Grieve M, ed. A modern herbal. New York Dover, 1971.Google Scholar
  4. 4.
    Bigus A, Massengil D, Walker C. Hawthorn, http://www.unc.edu/∼cebradsh/main.html. Date accessed: Oct 15, 1998.
  5. 5.
    Tyler VE. The Honest Herbal, 3rd edition. Binghamton Pharmaceutical Products Press, 1993.Google Scholar
  6. 6.
    Blumenthal M, ed. Popular Herbs in the U.S. Market. Austin American Botanical Council, 1997.Google Scholar
  7. 7.
    Williamson JS, Wyandt CM. Herbal therapies: the facts and the fiction. Drug Topics 1997;141:78–85.Google Scholar
  8. 8.
    Bahorun T, Gressier B, Trotin F, et al. Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations. Arzneim Forsch 1996;46:1086–1089.Google Scholar
  9. 9.
    Anonymous. Hawthorn (Crataegus monogyna). Nat Med 1999;2:5.Google Scholar
  10. 10.
    Iwamoto M, Sato T, Ishizaki T. The clinical effect of Crataegus in heart disease of ischemic or hypertensive origin. A multicenter double-blind study. Planta Med 1981;42:1–16.CrossRefGoogle Scholar
  11. 11.
    Blumenthal M, ed. The Complete German Commission E Monographs. Austin American Botanical Council, 1998.Google Scholar
  12. 12.
    Degenring FH, Suter A, Weber M, Sailer R. A randomized double blind placebo controlled trial of a standardized extract of fresh Crataegus berries (Crataegisan®) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine 2003; 10:363–369.PubMedCrossRefGoogle Scholar
  13. 13.
    Pittler MH, Schmidt K, Ernst E. Hawthron extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003; 114:665–674.PubMedCrossRefGoogle Scholar
  14. 14.
    Asgary S, Naderi GH, Sadeghi M, Kelishadi R, Amiri M. Antihypertensive effect of Iranian Crataegus curvisepala lind.: a randomized, double-blind study. Drugs Exp Clin Res 2004;5-6:221–225.CrossRefGoogle Scholar
  15. 15.
    Walker AF, Marakis G, Morris AP, Robinson PA. Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytother Res 2002;15:48–54.CrossRefGoogle Scholar
  16. 16.
    Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneim Forsch 1995;45:842–845.Google Scholar
  17. 17.
    Popping S, Rose H, Ionescu I, Fisher Y, Hammermeier H. Effect of a hawthorn extract on contraction and energy turnover of isolated rat caridiomyocytes. Arzneim Forsch 1995;45:1157–1160.Google Scholar
  18. 18.
    Rajendran S, Deepalakshmi PD, Parasakthy K, Devaraj H, Niranjali S. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996; 123:235–241.PubMedCrossRefGoogle Scholar
  19. 19.
    Ammon HO, Handel M. Crataegus toxicology and pharmacology. Part I: toxicity. Planta Med 1981;43:105–120.CrossRefGoogle Scholar
  20. 20.
    Canivenc-Lavier M, Vernavaut M, Totis M, Siess M, Magdolou J, Suschetet M. Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver. Toxicology 1996; 114:19–27.PubMedCrossRefGoogle Scholar
  21. 21.
    Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003;43:637–642.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Timothy S. Tracy

There are no affiliations available

Personalised recommendations